ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

INO vs MRK // GROSS PROFIT MARGIN

Inovio Pharmaceuticals Inc. (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: INO 0 — MRK 8
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (INO VS. MRK) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC INO MRK SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin ACTIVE — 74.80% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% 20.70% -55.70 MRK /roic <GO>
EV/EBITDA & P/E Valuation — 15.3x — TIE /valuation <GO>
Free Cash Flow Yield — 3.42% — TIE /fcf-yield <GO>
Operating Margin -60.00% 34.30% -94.30 MRK /operating-margins <GO>
Net Profit Margin -60.00% 28.10% -88.10 MRK /net-margins <GO>
Revenue Growth (YoY) -65.00% 1.30% -66.30 MRK /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 2.26% -2.26 MRK /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 5.19 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 7/9 -5.00 MRK /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 27.1 51.7 -24.65 MRK /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — 0.92 — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 18.4x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $79.8M $361.02B -$360.94B MRK /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR INO REV MRK REV INO GROSS % MRK GROSS % INO FCF MRK FCF
FY 2025 $65.3K $65.01B — 74.8% -$88.9M $12.36B
FY 2024 $217.8K $64.17B — 76.3% -$104.6M $18.10B
FY 2023 $832.0K $60.12B — — -$124.4M $10.30B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
INO // BETA —
MRK // BETA 0.92